Social determinants of pharmacological dementia management: results from IDEAS
These results suggest amyloid status, cognitive impairment level, dementia etiology, and comorbidities may inform pharmacological decision-making. Clarifying dementia etiology with amyloid PET may, for instance, help clinicians optimize treatment plans to address undermanaged depression in cognitively impaired older adults. Further, socioeconomic disadvantage may limit clinical response to amyloid-positivity. Replication in New IDEAS and examination of Medicare claims will help elucidate whether disparities in pre-PET management and management changes are primarily driven by access barriers to assessment and healthcare.
Authors
- Margo B. Heston (ORCID: https://orcid.org/0000-0002-0980-2275)
- Charles E. Apgar
- Barry A. Siegel (ORCID: https://orcid.org/0000-0001-6246-5792)
- Lucy S. Hanna
- Bruce E. Hillner
- Marı́a C. Carrillo
- Peggye Dilworth‐Anderson
- Consuelo H. Wilkins
- Gil D. Rabinovici
- Constantine Gatsonis
- Rachel A. Whitmer
- Andrew March
- Renaud La Joie
Institutions
- American College of Radiology (US)
- University of North Carolina at Chapel Hill (US)
- Alzheimer's Association (US)
- University of California, San Francisco (US)
- Virginia Commonwealth University (US)
- Washington University in St. Louis (US)
- Brown University (US)
- University of California, Davis (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_107370
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00